nach oben

Clinical Drug Investigation

Erschienen in:

01.01.2004 | Original Research Article

Esomeprazole 20mg Provides More Effective Intragastric Acid Control than Maintenance-Dose Rabeprazole, Lansoprazole or Pantoprazole in Healthy Volunteers

verfasst von: Dr Kerstin Röhss, Clive Wilder-Smith, Emma Nauclér, Lennart Jansson

Erschienen in: Clinical Drug Investigation | Ausgabe 1/2004

Einloggen, um Zugang zu erhalten

Abstract

Objective

A high proportion of patients with gastro-oesophageal reflux disease experience recurrence of symptoms within a year of initial treatment. The key to preventing relapse is an effective maintenance therapy that maintains intragastric pH >4. This study was conducted to compare the effects on intragastric pH of maintenance doses of four proton pump inhibitors: esomeprazole 20mg, lansoprazole 15mg, rabeprazole 10mg and pantoprazole 20mg.

Study participants and methods

Three standardised, randomised, two-way crossover studies were performed in a total of 108 Helicobacter pylori-negative healthy subjects. Intragastric pH was monitored on day 5 of once-daily oral dosing. The percentage of time of a 24-hour period with intragastric pH >4 and 24-hour median pH were measured on day 5.

Results

The mean percentage of time with intragastric pH >4 on day 5 was significantly longer following esomeprazole 20mg compared with either lansoprazole 15mg (esomeprazole 50.4% vs lansoprazole 43.0%, p = 0.026), rabeprazole 10mg (esomeprazole 59.8% vs rabeprazole 51.7%, p = 0.011) or pantoprazole 20mg (esomeprazole 59.6% vs pantoprazole 39.5%, p < 0.0001).

Conclusions

Maintenance dose esomeprazole 20mg provided greater acid control and maintained intragastric pH >4 for a longer period of time than maintenance dose lansoprazole 15mg, rabeprazole 10mg and pantoprazole 20mg in healthy subjects.

Hunt RH. Importance of pH control in the management of GERD. Arch Intern Med 1999; 159(7): 649–57PubMedCrossRef

Olbe L, Lundell L. Medical treatment of reflux esophagitis. Hepatogastroenterology 1992; 39(4): 322–4PubMed

Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adeno-carcinoma. N Engl J Med 1999; 340(11): 825–31PubMedCrossRef

Bell NJV, Burget D, Howden CW, et al. Appropriate acid suppression for management of gastro-oesophageal reflux disease. Digestion 1992; 51 Suppl. 1: 59–67PubMedCrossRef

Havelund TT, Lind T, Wiklund I, et al. Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. Am J Gastroenterol 1999; 94(7): 1782–9PubMedCrossRef

Revicki DA, Wood M, Maton PN, et al. The impact of gastro-esophageal reflux disease on health-related quality of life. Am J Med 1998; 104(3): 252–8PubMedCrossRef

Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112(6): 1798–810PubMedCrossRef

Lind T, Rydberg L, Kyleback A, et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14(7): 861–7PubMedCrossRef

Röhss K, Wilder-Smith C, Claar-Nilsson C, et al. Esomeprazole 40mg provides more effective acid control than standard doses of all other proton pump inhibitors [abstract]. Gastroenterology 2001; 120: A419

10.

Miner PB, Katz PO, Chen Y, et al. Gastric acid control with esomeprazole, omeprazole, pantoprazole and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98: 2616–20PubMedCrossRef

11.

National Institute for Clinical Excellence 2000. Guidance on the use of proton pump inhibitors (PPIs) in the treatment of dyspepsia [online]. Available from URL: http://www.nice.org.uk [Accessed 2003 Sep 12]

12.

DeVault KR, Castell DO, and The Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol} 1999}; 94}: 1434–42PubMedCrossRef

13.

Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management: the Genval workshop report. Gut 1999; 44 Suppl. 2: Sl–16

14.

Wilder-Smith C, Röhss K, Claar-Nilsson C. Esomeprazole 20mg provides more effective acid control than lansoprazole 15mg [abstract]. Gut 2000; 47 Suppl. 3: A62

15.

Röhss K, Claar-Nilsson C, Jansson L. Esomeprazole 20mg provides more effective acid control than rabeprazole 10mg following repeated drug administration. Scand J Gastroenterol 2002; 37(6 Suppl. 235): 2–38

16.

Nilsson-Pieschl C, Lundin C, Hjalmar K, et al. Esomeprazole 20mg provides faster and more effective acid control than pantoprazole 20mg in healthy volunteers. Scand J Gastroenterol 2003; 38Suppl 238: A–P3

17.

Howden CW, Burget DW, Hunt RH. Appropriate acid suppression for optimal healing of duodenal ulcer and gastro-oesophageal reflux disease. Scand J Gastroenterol 1994; 29 Suppl. 201: 79–82CrossRef

18.

Thomson ABR, Claar-Nilsson C, Hasselgren G, et al. Esomeprazole 40mg provides more effective acid control than lansoprazole 30mg during single and repeated administration [abstract]. Gut 2000; 47 Suppl. 3: 63

19.

Lauritsen K, Deviere J, Bigard M-A. Esomeprazole 20mg is more effective than lansoprazole 15mg in the maintenance treatment of patients with healed reflux oesophagitis. Aliment Pharmacol Ther 2003; 17(3): 333–41PubMedCrossRef

20.

Johnson DA, Vakil NB, Hwang C, et al. Impact of esomeprazole on symptom control in patients with healed erosive esophagitis [abstract 2247]. Gastroenterology 2001; 120(5 Suppl. 1): A441

21.

Blum RA, Shi H, Karol MD, et al. The comparative effects of lansoprazole, omeprazole and ranitidine in suppressing gastric acid secretion. Clin Ther 1997; 19(5): 1013–23PubMedCrossRef

22.

Tutuian R, Katz PO, Bochenek W, et al. Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40mg, in healthy volunteers. Aliment Pharmacol Ther 2002; 16: 829–36PubMedCrossRef

23.

Baisley KJ, Warrington S, Tejura B, et al. Rabeprazole 20mg compared with esomeprazole 40mg in the control of intragastric pH in healthy volunteers [abstract 148]. Am J Gastroenterol 2001; 96(9 Suppl. ): S48

24.

Warrington S, Baisley K, Boyce M, et al. Effects of rabeprazole, 20mg, or esomeprazole, 20mg, on 24-h intragastric pH and serum gastrin in healthy subjects. Aliment Pharmacol Ther 2002; 16: 1301–7PubMedCrossRef

25.

Hirschowitz BI. A critical analysis with appropriate controls of gastric acid and pepsin secretion in clinical esophagitis. Gastroenterology 1991; 101: 1149–58PubMed

Titel: Esomeprazole 20mg Provides More Effective Intragastric Acid Control than Maintenance-Dose Rabeprazole, Lansoprazole or Pantoprazole in Healthy Volunteers
verfasst von: Dr Kerstin Röhss
Clive Wilder-Smith
Emma Nauclér
Lennart Jansson
Publikationsdatum: 01.01.2004
Verlag: Springer International Publishing
Erschienen in: Clinical Drug Investigation / Ausgabe 1/2004
Print ISSN: 1173-2563
Elektronische ISSN: 1179-1918
DOI: https://doi.org/10.2165/00044011-200424010-00001

Springer Medizin

Abstract

Objective

Study participants and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2004

Long-Term Efficacy and Safety of Ipratropium Bromide plus Fenoterol via Respimat® Soft Mist™ Inhaler (SMI) versus a Pressurised Metered-Dose Inhaler in Asthma

Effect of Carvedilol on QT Duration in Paediatric Patients with Congestive Heart Failure

Impaired Rehabilitation Secondary to Muscle Weakness Induced by Meropenem

Survey of Symptom Burden in Women with Uncomplicated Urinary Tract Infections

Efficacy of Low-Dose Tamsulosin on Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia

Oseltamivir Distributes to Influenza Virus Replication Sites in the Middle Ear and Sinuses